Adipocytokine levels in benign prostate hyperplasia and prostate cancer patients

The occurrence of prostate cancer in men is one of the most common types of cancer. Recent studies have found important links between cancer and adipocytokines. Adipocytokines are thought to be factors in the occurrence of a variety of diseases. In addition, adipocytokines studies in cancer patients have shown that these hormones may have an effect in the formation of cancer. The objective of this study was to evaluate the relationship between adiponectin, resistin, and leptin levels in BHP and prostate cancer patients. The study was conducted between September 2012 and April 2013 at the Department of Medical Biochemistry and the Department of Urology. Blood samples were collected from 20 people in the same age range who had been diagnosed by examination and biopsy as having BHP (benign prostatic patients) and prostate cancer patients who had not been operated on. Leptin, adiponectin, resistin, and human serum levels were measured using ELISA kit. In the prostate cancer group, serum adiponectin and resistin levels were significantly lower than in the BHP group. However, serum leptin levels in the prostate cancer group were not significantly different from those in the BHP group. This information and our own findings show that adiponectin and resistin, which are from the adipocytokine family, may play an important role in the progression of prostate cancer, and thus it may be possible to use them as diagnostic markers. Therefore, similar studies should be considered with a greater number of patients at different stages. [Med-Science 2017; 6(3.000): 418-23